GUEST COLUMNISTS

• The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option

  Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.

• Planning A Global Clinical Trial With The Right Sites, Not The Most Sites

  Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

• Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

  Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

• Turning A Historically Limited Modality Into A Respiratory Drug Opportunity

  How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

• It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials

  Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

• Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy

  Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

• 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations

  Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

• What BriaCell's Trial Design Says About Real-World Cancer Research

  BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.